Other languages Tharimmune, Inc.

Equities

THAR

US4327052001

Real-time Estimate Cboe BZX Other stock markets 12:49:05 2024-05-23 pm EDT			5-day change	1st Jan Change
0.337 ^USD	+3.37%		-8.23%	-33.60%

May. 22	Tharimmune to Implement 1-for-15 Reverse Stock Split	MT
May. 09	Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tharimmune to Implement 1-for-15 Reverse Stock Split	May. 22
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	Apr. 23
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	Feb. 20
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	Feb. 05
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	Jan. 29
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease	Dec. 11
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	Dec. 11
Sector Update: Health Care Stocks Retreat in Late Afternoon	Nov. 28
Top Midday Decliners	Nov. 28
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	Nov. 28
Top Premarket Decliners	Nov. 28
Tharimmune Prices $10 Million Public Share Offering	Nov. 28
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	Nov. 27
Sector Update: Health Care Stocks Slipping Late Afternoon	Nov. 17
Sector Update: Health Care Stocks Softer Friday Afternoon	Nov. 17
Tharimmune to Implement 1-for-25 Reverse Stock Split	Nov. 17
Tharimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Tharimmune, Inc. Announces Execution of an Exclusive Worldwide Licensing Agreement with Avior Inc. D/B/A Avior Bio, Llc ("Avior") to Develop, Market and Commercialize A Clinical-Stage Asset, Av104 (To Be Renamed Th104 and Hereinafter Referred to as Th104)	Nov. 06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tharimmune, Inc.

Equities

THAR

US4327052001

Other languages

Filters